Veozah vs Myfembree
A side-by-side look at two women's health medications advertised on TV. Informational only — not medical advice.
| US Veozah | US Myfembree | |
|---|---|---|
| Generic name | fezolinetant | relugolix/estradiol/norethindrone |
| Drug class | NK3 Receptor Antagonist | GnRH Antagonist Combination |
| Treats | Menopausal hot flashes | Uterine fibroids and endometriosis |
| Category | Women's Health | Women's Health |
| Manufacturer | Astellas Pharma | Myovant Sciences |
| Year approved | 2023 | 2021 |
| FDA warning | Moderate warnings | Black box warning |
| Est. TV ad spend | $110M | — |
| Common side effects | Liver injury risk, Abdominal pain, Diarrhea, Insomnia | Bone density loss, Blood clot risk, Hot flashes, Abnormal bleeding |
Frequently asked questions
Is Veozah or Myfembree better?
Neither is universally "better." Veozah (fezolinetant) and Myfembree (relugolix/estradiol/norethindrone) are both used for women's health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Veozah and Myfembree?
Veozah is a NK3 Receptor Antagonist made by Astellas Pharma, while Myfembree is a GnRH Antagonist Combination made by Myovant Sciences. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Veozah has the larger estimated TV advertising budget of the two.